Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical mometasone vs hydrocortisone for prevention of acute radiation dermatitis in breast cancer
IRCT20180222038825N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer and radiodermatitis comparing Topical mometasone 0.1% with Topical hydrocortisone 1% (2 arms). Primary endpoint: Prevention of acute radiation dermatitis. Started May 2017; status: completed.
02
Drugs
mometasonehydrocortisone
03
Conditions
breast cancerradiodermatitis
Beyond the preview
Go deeper on IRCT20180222038825N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180222038825N1.